Tetraphase Pharmaceuticals Price Target Increased to $20.00 by Analysts at JMP Securities (TTPH)
Research analysts at JMP Securities increased their target price on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from $16.00 to $20.00 in a report released on Wednesday. The firm currently has an “outperform” rating on the stock. JMP Securities’ target price would suggest a potential upside of 52.91% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 8th. They set a “buy” rating and a $23.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 20th. Finally, analysts at Gabelli initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Friday, June 20th. They set a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $19.25.
In other Tetraphase Pharmaceuticals news, Insider Guy Macdonald unloaded 10,000 shares of the stock on the open market in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $11.59, for a total transaction of $115,900.00. The sale was disclosed in a filing with the SEC, which is available at this link.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 13.08 on Wednesday. Tetraphase Pharmaceuticals has a 52-week low of $8.01 and a 52-week high of $17.74. The stock has a 50-day moving average of $11.38 and a 200-day moving average of $11.41. The company’s market cap is $339.5 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Tuesday, August 12th. The company reported ($0.71) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.54) by $0.17. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.79 million. On average, analysts predict that Tetraphase Pharmaceuticals will post $-2.27 earnings per share for the current fiscal year.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.